We are live on
!
Find out more
Syndax Pharmaceuticals
SNDX
SNDX
246 hedge funds and large institutions have $2.32B invested in Syndax Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 99 increasing their positions, 68 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
86% more call options, than puts
Call options by funds: $15.2M | Put options by funds: $8.14M
80% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 25
46% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 68
11% more capital invested
Capital invested by funds: $2.1B → $2.32B (+$222M)
7% more funds holding
Funds holding: 229 → 246 (+17)
2.28% less ownership
Funds ownership: 114.94% → 112.66% (-2.3%)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
Holders
246
Holders Change
+17
Holders Change %
+7.42%
% of All Funds
3.03%
Holding in Top 10
10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-9.09%
% of All Funds
0.12%
New
45
Increased
99
Reduced
68
Closed
25
Calls
$15.2M
Puts
$8.14M
Net Calls
+$7.04M
Net Calls Change
-$8.56M
Top Buyers
| 1 |
DM
Deerfield Management
New York
|
+$82.1M |
| 2 |
O
OrbiMed
New York
|
+$20.9M |
| 3 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
+$15.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$9.71M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$9.5M |
